# A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

> **NCT07292168** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kidney Cancer Research Bureau** · enrollment: 58 (estimated)

## Conditions studied

- Renal Cell Carcinoma Metastatic
- Prostate Cancer Metastatic
- Non-small Cell Lung Cancer Metastatic
- Breast Cancer Metastatic
- Head & Neck Cancer

## Interventions

- **BIOLOGICAL:** humanized monoclonal anti-FGFR1 antibody OM-RCA-01

## Key facts

- **NCT ID:** NCT07292168
- **Lead sponsor:** Kidney Cancer Research Bureau
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07292168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07292168, "A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT07292168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*